                         SEQUENCE LISTING

<110>  MedImmune, LLC
       Unitract Syringe Pty Ltd
 
<120>  Tralokinumab Delivery Device

<130>  86867.0004\PCT

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  122
<212>  PRT
<213>  Artificial

<220>
<223>  VH region of mAb BAK502G9 (tralokinumab)

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Gln Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Asn Asn Gly Asp Thr Asn Tyr Gly Gln Glu Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Ser Ser Ser Ser Trp Ala Arg Trp Phe Phe Asp Leu Trp 
            100                 105                 110         


Gly Arg Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  2
<211>  108
<212>  PRT
<213>  Artificial

<220>
<223>  VL region of mAb BAK502G9 (tralokinumab)

<400>  2

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Gly Gly Asn Ile Ile Gly Ser Lys Leu Val 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Asp Asp Gly Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Thr Gly Ser Asp Pro 
                85                  90                  95      


Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of mAb BAK502G9 heavy chain

<400>  3

Asn Tyr Gly Leu Ser 
1               5   


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of mAb BAK502G9 heavy chain

<400>  4

Trp Ile Ser Ala Asn Asn Gly Asp Thr Asn Tyr Gly Gln Glu Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of mAb BAK502G9 heavy chain

<400>  5

Asp Ser Ser Ser Ser Trp Ala Arg Trp Phe Phe Asp Leu 
1               5                   10              


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR1 of mAb BAK502G9 light chain

<400>  6

Gly Gly Asn Ile Ile Gly Ser Lys Leu Val His 
1               5                   10      


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR2 of mAb BAK502G9 light chain

<400>  7

Asp Asp Gly Asp Arg Pro Ser 
1               5           


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR3 of mAb BAK502G9 light chain

<400>  8

Gln Val Trp Asp Thr Gly Ser Asp Pro Val Val 
1               5                   10      


